INDUSTRY AND FINANCE



Key Takeaways

0.86 R2 and **1.7 MAE** prediction metrics were achieved for recruitment rates.

Critical features important for prediction were engineered.

Assumptions

Disease prevalence is quantified using WHO DALYs data.

Recruitment competition is calculated by tracking overlapping trials in the same region.

Eligibility complexity is measured using Shannon entropy.

Conclusion

Higher recruitment competition or complex eligibility criteria reduce predictability, emphasizing the need for optimised trial design.

References

Accelerating clinical trials to improve biopharma R&D productivity, McKinsey & Co

Examination of Clinical Trial Costs and Barriers for Drug Development, U.S. Department of Health and Human Services on policy development.

Best Practices and Assumptions for Clinical Trial Budgeting, Mythri Raghunandan, Clinical Research Specialist

TrialX Blog: Clinical trial failures losses of 2016